Congenital sucrase-isomaltase deficiency is an example of a disease in which mutant phenotypes generate transportincompetent molecules. Here, we analyze at the molecular level a phenotype of congenital sucrase-isomaltase defi ciency in which sucrase-isomaltase (SI) is not transported to the brush border membrane but accumulates as a mannoserich precursor in the endoplasmic reticulum (ER), E R -Golgi intermediate compartment, and the c/s-Golgi, where it is finally degraded. A 6-kb clone containing the fulllength cDNA encoding SI was isolated from the patient's intestinal tissue and from normal controls. Sequencing of the cDNA revealed a single mutation, A/C at nucleotide 3298 in the coding region of the sucrase subunit of the en zyme complex. The mutation leads to a substitution of the glutamine residue by a proline at amino acid 1098 (Q1098P), The Q1098P mutation lies in a region that is highly con served between sucrase and isomaltase from different spe cies and several other structurally and functionally related proteins. This is the first report that characterizes a point mutation in the SI gene that is responsible for the transport incom petence of SI and for its retention between the ER and the Golgi. (J. Clin. Invest. 1996. 97:633-641.) 
Introduction
The highly organized cascade of processing and modification events along the biosynthetic pathway of secretory and mem brane proteins has led to the general concept of compartmentalization of the cell into structurally and functionally distinct organelles (1) (2) (3) (4) . Conformational modifications of membrane and secretory proteins commence already during their translo-cation across the endoplasmic reticulum (ER )1 membrane and continue in the E R lumen (4) (5) (6) . Among the most important modifications are those elicited by cotranslational glycosylation, inter-or intramolecular disulfide bond formation, and subunit assembly known as oligomerization (5, 7, 8) . These events are considered to be rate limiting along the exocytic pathway. However, modifications in the Golgi, such as acquisi tion of a complex type of oligosaccharides, have bêen fre quently reported to confer effects also on the transport kinet ics of proteins to the cell surface and secretion into the external milieu (9) (10) (11) (12) . Analysis and identification of the vari ous steps of the secretory pathway and dissection of the molec ular mechanisms adequate for efficient transport of membrane and secretory proteins to the cell surface have been success fully investigated in naturally occurring mutant phenotypes of proteins with impaired targeting (for review see reference 13) .
Congenital sucrase-isomaltase deficiency (CSID) has been used to characterize various steps in the biosynthesis, trans port, and sorting of sucrase-isomaltase (SI) as a model for cell surface membrane proteins (14) (15) (16) (17) . CSID is an autosomal re cessive disorder of the small intestine that is clinically mani fested as a watery osmotic-fermentative diarrhea upon inges tion of di-and oligosaccharides. Epithelial cells of patients with this disease lack the sucrase activity of the enzyme SI, while the isomaltase activity can vary from absent to practi cally normal.
SI is a type II integral membrane glycoprotein that is exclu sively expressed in the small intestinal microvillar membrane (18) and is responsible for the terminal digestion of dietary su crose and starch (for review see reference 19) . The glycopro tein comprises two subunits that are highly homologous and are thought to be derived from the same ancestral gene (20) . These two subunits are associated with each other by strong noncovalent, ionic interactions (19, 21) . SI is synthesized in the rough E R as a single chain mannose-rich precursor comprising both subunits (pro-SIh, 210 kD) (22) , It is transported to the Golgi apparatus at a relatively slow rate and does not form ho modimers before ER exit (11) . The strong homologies be tween the two main domains suggest that quasi-dimers or pseudo-dimers (8) are formed, which are presumably sufficient for acquisition of transport competence. After modification of the N-linked glycans and O-glycosylation, SI is sorted to the apical membrane and cleaved in situ by lumenal pancreatic proteases to its two active subunits, sucrase and isomaltase (22, 23) .
The molecular basis of CSID is still not elucidated. How ever, it has been proposed that different molecular defects or mutations in the SI gene are responsible for CSID (24) . This hypothesis has been strongly supported by the analysis of sev eral cases of CSID, which has led to the identification of five different phenotypes of SI (14, 17) . Phenotypes I and II, for in stance, are characterized by an intracellular accumulation of marinose-rich SI in the ER and the Golgi, respectively. In phe notype III an enzymatically inactive, but transport-competent, SI is expressed. Phenotype IV expresses a partially folded, mannose-rich SI molecule that is missorted to the basolateral membrane. Finally, phenotype V reveals an SI species that un dergoes intracellular degradation leaving behind the isomal tase subunit that is correctly targeted to the brush border membrane. In this paper we analyzed a biopsy specimen of CSID phenotype II and demonstrated that SI is located in the ER, the intermediate compartment and the c/s-Golgi. We show for the first time that a single point mutation is responsi ble for the impaired transport behavior of SI.
Methods
Antibodies. Four epitope-specific mAbs directed against sucrase, iso maltase, or SI were used (25) . These antibodies were products of the following hybridomas: HBB 1/691, HBB 2/614, HBB 2/219, and HBB 3/705. mAb anti-human lactase-phlorizin hydrolase (mAb anti-LPH) and mAb anti-human aminopeptidase N (mAb anti-ApN) were products of hybridomas HBB 1/909 and HBB 3/153, respectively (25) . mAb anti-ER-GoIgi intermediate compartment-53 (anti-ERGIC-53) was a product of hybridoma Gl/93 (26) . All mAbs were gener ously provided by Dr. H. P. Hauri (Biocenter, Basel, Switzerland) and Dr. E. E. Sterchi (University of Bern, Bern, Switzerland).
Cell lines. Caco-2 cells (ATCC HTB-37) were cultured in Dulbecco's modified Eagle's medium (DME) supplemented with 20% heat-inactivated fetal calf serum (FCS), 1% nonessential amino acids and antibiotics (all from GIBCO BRL, Gaithersburg, MD). Monkey kidney COS-1 (ATCC CRL-1650) cells were cultured in DME sup plemented with 10% FCS and antibiotics. All cell lines were cultured at 37°C in a humidified 5% C 0 2 incubator.
Processing o f biopsy samples. The patient with CSID had a life long history of abdominal pain, cramps, and osmotic diarrhea upon ingestion of sucrose. CSID was assessed by the breath hydrogen test and by sucrose tolerance test. CSID was further confirmed by enzyme activity measurements of sucrase and isomaltase in intestinal biopsy homogenates (27) . Control intestinal tissue was taken from patients screened for diagnostic purposes other than CSID. Peroral suction in testinal biopsy samples from CSID and controls were taken from the upper jejunum and were histologically normal. Five biopsy samples were obtained from each patient and immediately processed as fol lows. One sample was cut into small pieces and fixed for immunoelectronmicroscopy (see later). One sample was frozen in liquid nitrogen for RNA preparation. Three samples were biosynthetically labeled in organ tissue culture dishes (Falcon Division, Becton Dickinson, Lin coln Park, NJ) on stainless steel grids according to Naim et al. (28) . Here, the tissue was labeled continuously with 150 |mCi of [35S]methionine (//w2s-[3SS]methionine, > 1,000 |j-Ci/mmol; ICN Biomedi cals, inc., Carson, CA) for 0.5, 4, or 18 h. After the labeling periods, the specimens were washed three times in RPMI 1640 (GIBCO BRL) and homogenized at 4°C with a Teflon glass homogenizer in 1 ml of homogenization buffer (25 mM Tris-HCl, 50 mM NaCl, pH 8.1), and a cocktail of protease inhibitors containing 1 mM PMSF, 1 (xg/ml pepstatin, 5 jjig/ml leupeptin, 17.4 i-Lg/ml benzamidine, and 1 jjLg/ml apro-tinin (all from Sigma Immunochemicals, St. Louis, MO). The homo genates were either further processed directly for immunopréci pitation or kept frozen at -20°C until use.
Synthesis and construction ofcDNA encoding pro-Slfrom Caco-2 cells and from tissue o f control individuals and CSID patients. Re agents and methods for routine recombinant DNA techniques and PCR were as described previously (29, 30) . Cloning of the SI cDNA from the patient's mucosal cells, control biopsies, and Caco-2 cells followed a similar strategy. Total RNA isolation and cDNA synthesis were performed as described by Moolenaar et al. (31) . Total RNA was isolated from postconfluent Caco-2 cells using the guanidiniumisothiocyanate method (32) . Randomly primed cDNA was synthe sized from ). Double-stranded DNA was dissociated at 94°C for 45 s, the annealing step was at 55°C for 1 min, and the extension step was at 70°C for 1.5 min. The reactions were subjected to 30 cycles of amplification, Some of the primers used in the PCR reactions were designed based on the published sequences of the rabbit and human SI cDNA (34, 35) . Table I shows the position of these primers within the SI cDNA. The products of two independent PCR reactions were directly or after cloning into pGEM4Z sequenced with a DNA se quencing kit according to the instructions of the manufacturer (Sequenase V. 2.0; United States Biochemical Corp., Cleveland, OH).
The various DNA fragments of wild-type SI cDNA were li gated together and cloned into the expression vector pCB7 (36) to generate the plasmid phSI encoding wild-type pro-SL Se quencing of the DNA fragments obtained by PCR from the CSID tissue revealed a single mutation A/C at nucleotide 3298. This mutation was found in the PCR product encompassing nu cleotides 2967-4201. A 619-bp (Ncol-Apal) fragment containing this mutation was purified and exchanged with its counterpart in the wild-type phSI plasmid. The generated plasmid was denoted phSIa/c. Transfection and metabolic labeling of COS-1 cells. COS-1 cells were either transfected by the DEAE-dextran method as described by Naim et al. (29) or via electroporation in a gene puiser (Bio-Rad Laboratories, Richmond, CA): a 0.4-cm cuvette containing 200 |xl icecold PBS with 1.5 million cells and 10 jxg DNA was exposed to 0.3 kV and 125 jxF. Transiently transfected COS-1 cells were metabolically labeled with 80 juuCi L-[35S]methionine (ICN Biomedicals, Inc.) as de scribed by Naim et al. (29) . After the labeling period, the cells were washed and stored at -70°C until use.
Immunoprécipitation. Homogenates of biosynthetically labeled biopsy specimens were lysed on ice by addition of Triton X-100 and sodium deoxycholate to final concentrations of 0.5% each (28) . Biosynthetically labeled transfected COS-1 cells were lysed at 4°C for 1 h in lysis buffer (25 mM Tris-HCl, pH 8.0, 50 mM NaCI, 0.5% Triton X-100, 0.5% sodium deoxycholate, and a mixture of protease inhibi tors containing 1 mM PMSF, 1 (xg/ml pepstatin, 5 jAg/m! leupeptin, 17,4 |JLg/ml benzamidine, and 1 jxg/ml aprotinin). Usually 1 ml ice-cold lysis buffer was used for each 100-mm culture dish (~ 2-4 X 10fl cells). Detergent extracts of cells or biopsy samples were centrifuged for 1 . h at 100,000 g at 4°C and the supernatants were immunoprecipitated as described by Naim et al. (17, 22, 28, 29) , Four epitope-specific mAbs directed against sucrase, isomaltase, or SI were used (25) . These antibodies were used in the form of ascites. Usually, 0.5-1 pi ascites was used for each immunoprécipitation, For epitope mapping sludies with four mAbs directed against SI the extracts of biopsy sam ples were divided into equal aliquots and each aliquot was immunoprecipitated with a different antibody.
Immunofluorescence. Cellular localization of expressed proteins in COS-1 cells was studied with cells grown on coverslips. Cells were fixed with 3% paraformaldehyde and immunolabeling was carried out after 0.1% Triton X-100 permeabilization, using mAb anli-SI (HBB1/614) (1:1,000) and mAb anti~ERGIC~53 (Gl/93) (1:100) as the primary antibodies. The secondary antibodies used FITC-conjugated goat anti-mouse or anti-rabbit IgG (1:100), Texas red-conju gated goat anti-mouse or anti-rabbit IgG (1:200) (all were from Boehringer Mannheim Corp.). Cell surface localization of proteins was assessed in transfected cells that were incubated on ice with the pri mary antibody before fixation and without incubation with Triton X-100. The cells were visualized with a confocal laser microscope us ing a double channel for F1TC and Texas red and/or with a routine fluorescence microscope.
Immunoeiectron microscopy. Biopsy samples were cut into small pieces and fixed in a mixture of 2% formaldehyde and 0.1 % glutaraldehyde for 1 h at room temperature. They were then stored in 2% formaldehyde until use. Cryosectioning and immunolabeiing with anti-SI, anti-ERGIC-53, and protein A-goId were performed as de scribed previously (26, 37) .
Other procedures. SDS-PAGE was performed according to the method of Laemmli (38) . High molecular weight markers from Sigma Immunochemicals were used as a reference. Treatment of immunoprecipitates with Endo-N-acetylglucosaminidase H (Endo H), Endo-Af-acetylglucosaminidase F/glycopeptidase F (Endo F/GF, also known as PNGase F) (both from Boehringer Mannheim Corp.) was done as described before (28) .
Results
Initial assessment of CSID in the patient was achieved by the breath hydrogen test. Subsequently a biopsy specimen was taken from the upper jejunum and enzymatic activity measure ments of the disaccharidases, SI, and LPH were performed. Here, no activity of sucrase or isomaltase could be detected, while the activity of LPH was in the normal range of the control tissue (16-32 IU/mg protein). Likewise, normal activity of another control brush border enzyme, ApN, was revealed in the patient's biopsy sample. Therefore, the results pointed to an enzymatic defect that is restricted to SI. Previous analyses of several cases of SI deficiency have demonstrated that SI is synthesized as in normal controls, but is not correctly pro cessed or transported along the secretory pathway ('14,17) . We therefore set out to analyze the biosynthesis and processing of SI in the patient's tissue. Metabolic labeling of biopsy samples and immunoprecipitation of the detergent extracts with four different epitope-specific monoclonal anti-SI antibodies re vealed after 30 min of labeling an Endo H-sensitive 210-kD polypeptide that corresponds to mannose-rich pro-Sf (Fig. 1,  lanes 1-3) . This polypeptide remained the predominantly la beled species after 4 and 18 h of labeling (Fig. 1, lanes 4-9) . In the control biopsy specimen, by contrast, the Endo H-sensitive mannose-rich pro-SI ( Fig. 1, lanes 10-12) was processed to a complex glycosylated Endo H-resistant form after 4 h of labeling ( Fig. 1, lanes 13-15) . When comparing the metabolic labeling intensity of the patient's material after 4 and 18 h of labeling, no increase is observed as compared with the control (Fig. 1 , lanes 4-6 and 7-9 vs. lanes 10-12 and 13-15) . From these data we conclude that no processing of the patient's St in the Golgi ap paratus has occurred and that the protein is finally degraded.
To determine whether the impaired processing is the con sequence of general cellular defect or is restricted to SI, the transport of other brush border proteins was investigated. ApN and LPH were synthesized and processed in the patient's intestinal cells in a fashion similar to control cells (Fig. 2, lanes   1-8) . Thus, within 1 h of chase ApN was detected in the pa tient's biopsy sample as an Endo H-sensitive mannose-rich 130-kD polypeptide, which was converted into an Endo H-resistant 160-kD polypeptide after 20 h of chase (Fig. 2,   lanes 3 and 4) . Similarly no changes in the biosynthetic pattern of LPH could be observed. Here, LPH was synthesized as a 215-kD mannose-rich species that was cleaved intracellularly to the mature 160-kD polypeptide (Fig, 2, lanes 7 and 8) .
Therefore, the failure of mannose-rich SI to mature to an Endo H resistant species is indeed restricted to this molecule and is not the result of a general cellular defect since two con trol proteins, ApN and LPH, were processed to their mature forms and transported normally in the patient's tissue. -15) were biosynthetically labeled for the indicated times with [35S]methionine, The specimens were homogenized, solu bilized, and immunoprecipitated with monoclonal anti-SI antibodies. The immunoprecipitates were subjected to SDS-PAGE on 5% slab gels without treatment (lanes 7,4, 7, 70, and 13) or after Endo H (lanes 2 ,5, 8, I f and 14) or Endo F (lanes 3, 6y 9, i2, and 15 ) treat ment. Gels were analyzed by fluorography. Fig. 1 , the supernatant? depleted from SI were immunoprecipitated sequentially with mAb anti -ApN (lanes 1-4) or mAb anti-LPH (lanes 5-8) . The immunoprecipilates were analyzed by SDS-PAGE on 5% slab gels without treatment (lanes i, 3 ,5, and 7) or af ter Endo H (lanes 2 ,4> 6, and 8) treatment.
A Point Mutation Leads to a Golgi Block in Sucrase-Isomaltase Deficiency
Since SI is synthesized at almost normal levels in the pa tient's tissue but does not mature, we wanted to determine the subcellular localization of SI in the patient's epithelial cells.
Here, ultrathin cryosections of the patient's tissue were incu bated with monoclonal anti-SI antibodies followed by protein A-gold. The subcellular localization was finally assessed by electron microscopy (Fig. 3) . While most of the labeling in the control intestinal cells was confined to the brush border mem brane, no labeling of the brush border membrane in the pa tient's tissue could be detected (Fig. 3, A and B) . Instead, in tense labeling of the ER and Golgi cisternae was observed in the patient's tissue ( Fig. 3 D ) t while the Golgi apparatus and the ER of the control were weakly labeled ( Fig. 3 C) . The lat ter case reflects the normal steady state situation in biopsy samples (14) . Finally, both specimens, the patient's as well as the control's, did not show any labeling of the basolateral membrane.
The SI labeling in the patient's cells was visible on one side of the Golgi (Fig. 3 £) , arrows) and corresponds most likely to the c/s-Golgi and ERGIC. This is based on the labeling pattern obtained when biopsy samples are labeled with antibodies against ERGIC-53, a marker of the cz's-Golgi as well as E R GIC (Fig. 4 ). It should be noted that in the patient's biopsy material more label was observed for ERGIC-53 than in the control biopsies (compare Fig. 4, A and B) . In addition, ER-GIC-53 was also observed in the cisternae on one side of the Golgi apparatus in contrast to control biopsies where only a tubulo-vesicular structure on one side of the Golgi was labeled ( Fig. 4 A\ reference 26 ). Based on morphological criteria we conclude that the labeling of ERGIC-53 in the patient's biopsy coincides with the label of SI (compare Figs. 3 D and 4 B ) , al though a direct double labeling of SI and ERGIC-53 proteins could not be performed. The antibodies used to detect these proteins are both mAbs and these are difficult to combine in im mu nogold double staining experiments. Control experi ments using antibodies against the brush border glycoproteins LPH and ApN demonstrated localization of these proteins in the apical membrane (not shown).
Altogether, the data demonstrate that in the patient's bi opsy the SI molecule has egressed the E R and is arrested in an ERGIC-53-positive, dy-Golgi compartment where it is finally degraded. The phenotype therefore resembles phenotype II of CSID described previously (17) .
It is likely that the transport block of SI in the ERGIC,cis-Golgi, and ER as well as the persistence as a mannose-rich polypeptide are the consequence of structural alterations in the SI molecule. To examine this possibility, we performed epitope mapping using four different epitope-specific mono clonal anti-SI antibodies, HBB 2/614, HBB 2/219, HBB 1/691, and HBB 3/705. Except for mAb HBB1/691 all other antibod ies were able to recognize epitopes on mutant SI (not shown). The results imply that the epitope of HBB 1/619 did not ma ture in the patient's SI and was altered. Drastic alterations in the protein folding of SI did not presumably take place, since three out of four antibodies have recognized the mutant SI.
To analyze the molecular defects in this phenotype, we cloned the full-length cDNA encoding wild-type SI from Caco-2 cells and from the patient's biopsy sample. Construc tion of full-length cDNA encoding wild-type SI was performed by combining two approaches. The first used conventional screening of a Xgt-11 expression library made from the colon carcinoma cell line, Caco-2. Here, a clone comprising 1486 bp from nucleotides 550 to 2036 (base pair numbering according to Green et al. [35] ) and covering almost 50% of the isomaltase subunit was isolated. This clone was denoted IM21.1 (Lacey, S.W., unpublished observations). In the second ap proach we made use of the published sequences of rabbit and human SI (20, 34) . Many oligonucleotides were designed and used to amplify SI DNA fragments using RT-PCR on RNA extracted from Caco-2 cells or biopsy samples. These frag ments and the IM21.1 clone were ligated together to generate the full-length pro-SI cDNA. Sequencing of this clone re vealed two nucleotide differences versus the published se quence (34). These differences are not due to PCR artifacts, as assessed by sequencing of PCR products of two independent PCR reactions. One difference is A/G at nucleotide 4001 which represents a silent mutation. The second variation, a C/G at nucleotide 3612, leads to a glutamic acid instead of glutamine at amino acid 1203 in the sucrase subunit. Compari son with the amino acid sequences of rat and rabbit and our patient's (see below) sucrase subunits revealed also a glutamic acid residue at this particular position. Moreover, the human and rabbit isomaltase also contained a glutamic acid in the cor responding homologous stretch. Therefore, it is likely that the glutamine/glutamic acid exchange represents a polymorphism in the published sequence. To test the full-length cDNA, it was cloned into the pCB7 expression vector and transiently ex pressed in COS-1 cells. Metabolic labeling of these cells showed that SI is processed as in normal control samples (Fig.   5, lanes 1-3, compare with Fig. 1, lanes 10-15) . Also, when ex pressed in COS-1 cells, cell surface expression could be ob served (Fig. 6, A and B) .
To isolate a full-length SI cDNA encoding SI in the CSID tissue, a similar strategy was followed as for wild-type SI. The PCR products derived from two independent reactions were cloned and sequenced. The sequence analysis revealed one al teration relative to the SI cDNA cloned from Caco-2 cells. This alteration, A/C at nucleotide 3298, was found in the se quence encoding the S of the SI complex and resulted in a sub stitution of the glutamine 1098 by a proline (Q1098P), The mutation was confirmed by direct sequencing of several inde pendent PCR products. The wild-type sequence could never be identified, suggesting that both alleles of the SI gene con tain this mutation or, more likely, that one allele is not ex pressed.
The patient's cDNA was also cloned into the expression vector pCB7 and transiently expressed into COS-1 ceils. Again, metabolically labeled COS-1 cells showed that mutant cDNA is processed as in the patient's biopsy (Fig. 5, lanes 4-6,  compare with Fig. 1, lanes 1-9) , In addition, localization stud ies showed that the patient's SI is not expressed at the cell sur face of COS-1 cells, but instead accumulates intracellulariy in the ER and ERGIC, as shown by immuno double-labeling on transiently transfected cells (Fig. 6, C and D) . Figure 4. Immunocy to chemical localization of ERGIC-53 in C SID and normal control. Localization of ERGIC-53 was performed on ultrathin cryosections from a control biopsy (A ) and from the patient's biopsy (B ) using antibody Gl/93, followed by rabbit anti-mouse and protein A-10 nm gold staining. (A ) In the control biopsy vesicular structures on the cis~side of the Golgi apparatus are stained; (B) in contrast, in the patient's biopsy the labeling is not only stronger, but also additional staining over cisternae on one side of the Golgi is observed. Morphologically the label coincides with that observed for SI (compare with Fig. 3 D ) . Bar, 0,25 jxm.
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Endo Upon comparison, lysosomal a-glucosidase, Schwanniomyces occidentalis glucoamylase, sucrase, and isomaltase from various species share striking similarities in their amino acid sequences. This has led to the hypothesis that these molecules are derived from a common ancestral gene (39) . Sequence comparison revealed that the mutation Q1098P in the S sub unit is located in a stretch of 10 amino acids that is highly ho mologous among sucrase (amino acids 1093-1116), isomaltase (amino acids 219-243), lysosomal a-glucosidase (amino acids 239-262) and Sch. occidentalis glucoamylase (amino acids 196-220) ( Fig. 7 ).
Discussion
CSID has been used to characterize various steps in the bio synthesis, transport, and sorting of SI as a model for cell sur face membrane proteins. Several different phenotypes of CSID have been meanwhile described (14) (15) (16) (17) . In all of these CSID phenotypes, the transport incompetence, aberrant enzy matic function, or missorting to the basolaterai membrane is exclusively restricted to the SI molecule, ruling out a possible general cellular defect.
While analyses of the current and previous phenotypes at the subcellular and protein levels lent strong support to the hy pothesis that a point mutation in the c D N A of SI is responsible for the generation of CSID, the present data provide the first definite evidence that this is in fact the case. Here, we could characterize a point mutation in the region encoding the su crase subunit of the SI complex which converts a glutamine to a proline (Q1098P).
Therefore, the CSID malabsorption is another example of a clinical disorder or disease that ensues by single amino acid (40), collagen-based diseases, and familial hyper cholesterolemia (41) , just to name a few, are more severe (for review see reference 13).
A rather unusual mutant form of SI is generated in CSID phenotype II. Here, SI exits the E R and is transported to the medial and tmns-GoIgi where it undergoes degradation (17) . To our knowledge, no mammalian cell surface membrane gly coprotein has been so far identified that has efficiently egressed the E R and arrived in the Golgi cisternae where its transport is blocked. This strongly suggests that there are other criteria, in addition to the acquisition of correct folding and quaternary structure in the E R , that may modulate and control protein transport within the Golgi and to the cell surface.
The phenotype of SI described in this paper is very much similar to phenotype II (1.7). Analyses of the structural fea tures of SI in this phenotype by epitope mapping and biosyn thetic labeling reveal that incomplete initial folding of the SI precursor protein is responsible for the observed inefficient transport of the molecule along the secretory pathway. An ef fect of the oligomeric state of SI could be excluded since hu man SI does not dimerize and exits the E R efficiently as a mo nomeric molecule (8) .
The most interesting aspect of phenotype II is the ability of SI to egress the E R to the Golgi, while still in an incompletely or partially folded state. The subsequent arrest and final deg radation of SI in a c/s-Golgi compartment or in the Golgi is un usual and, except for SI, has not been demonstrated for an en dogenous protein destined for the cell surface. This is surprising since membrane and secretory proteins are believed to acquire transport competence in the E R and leave this or ganelle en route to their final destination.
It is generally accepted that a quality control mechanism A Point Mutation Leads to a Golgi Block in Sacnise-lsomaltase Deficiency 639 (20), rat sucrase (45), human isomaltase (32) , rabbit isomaltase (20) , human lysosomal a-glucosidase (43) , and Sch. occi dentalis glucoamylase (39) are aligned. The numbering and arrow in dicate the position in this highly conserved region where in the pa tient's SI the Q1098P mutation is located.
exists in the E R that sorts correctly folded from malfolded pro teins and retains the latter In the E R (5) (6) (7) 42) . H ow could phe notype II of C SID be accommodated within these general views and concepts? Human lysosomal a-glucosidase (43) and the yeast Sch. oc cidentalis glucoamylase (39) share striking homologies with human, rat, and rabbit S and I species and have been suggested to be evolved from a common ancestral gene (39) . O f interest, the Q1098P mutation is located within a stretch of the S sub unit that is homologous to lysosomal a-glucosidase and Sch. occidentalis glucoamylase (Fig. 7) . These proteins are all syn thesized and translocated into the E R where they are pro cessed to transport-competent forms and are then transported along, the secretory pathway to their final destinations. While SI is, sorted in the rram-Golgi network to the apical membrane, lysosomal a-glucosidase is mainly transported to the lysosomes after phosphorylation in the cw-Golgi and maturation in the medial and trans-Golgi. Sch. occidentalis glucoamylase is trans ported to the periplasmic space and partially secreted into the exterior milieu in yeast. Obviously all three proteins share a common pathway from the E R to the Golgi and from there di verge. to different destinations. Therefore, it is conceivable that homologies in the polypeptide sequences should be implicated in the biological function or transport mechanisms common to all of these proteins. Consistent with this is the observation that the regions containing the active catalytic centers of these proteins have almost identical amino acid sequences (34). If the mutation Q1098P does not initially induce gross conforma tional change in the S subunit, but rather alters a subdomain around the mutation that is critical for the intracellular trans port of the SI protein or creates a retention signal, then a simi lar effect would be also expected if the mutation is introduced into the corresponding homologous regions of lysosomal a-glucosidase or Sch . occidentalis glucoamylase.
It is possible that in the particular case of proteins with multidomain structure, such as SI, complete maturation of all protein domains is not absolutely required for egression from the ER, whereby the folding of some domains may be more es sential or critical than others in the context of the overall con formation. SI is composed of two large homologous domains that may fold independently (Naim, H.Y., unpublished obser vations) and it is reasonable to assume that the presence of the mutation in the sucrase subunit leads to alterations in its struc ture while the entire isomaltase subunit remains unaffected. While these alterations could be tolerated by the quality con trol mechanism in the E R , they could be crucial for the further secretory pathway of SI via the Golgi to the cell surface. R e cent data with a temperature-sensitive mutant of vesicular sto matitis virus glycoprotein have proposed a quality control mechanism outside the E R that prevents immature vesicular stomatitis virus glycoprotein from traversing the Golgi (44) .
Mutant SI phenotype II m ay be subject to a similar mechanism that operates via a putative retention signal created by the Q 1 0 9 8 P mutation. W e conclude that the simplest and most straight forward explanation for the phenotype described in this paper is that the mutation Q 1 0 9 8 P has created a signal or conformational change in the sucrase subunit which retains the enzyme com plex in a cis-Golgi compartment, where it is finally degraded by an unkno w n quality control mechanism operating at a level beyond the ER.
